

***One size does not fit all.  
Individual sepsis therapy in the  
Emergency Room?***

**Peter Kanizsai**


lead emergency physician

University of Pécs

Clinical Centre

Emergency Department

## The 5 Steps of Evidence-Based Medicine



<https://www.healthcatalyst.com/5-reasons-practice-evidence-based-medicine-is-hot-topic>

# Evidence-Based Medicine: A Unified Approach

Two approaches to using evidence to solve clinical problems, and how to unify them.

by David M. Eddy


HEALTH AFFAIRS - Volume 24, Number 1


2005


EBG (guidelines)

EBID(individual decisions)


- Daily examination of the patients
- Daily drug and fluid chart assessment
- Practice of adequate infection control
- Daily revision of individual treatment/nursing plan







Rivers E et al. N Engl J Med. 2001



### **SURVIVING SEPSIS CAMPAIGN BUNDLES**

#### **TO BE COMPLETED WITHIN 3 HOURS:**

- 1) Measure lactate level
- 2) Obtain blood cultures prior to administration of antibiotics
- 3) Administer broad spectrum antibiotics
- 4) Administer 30 mL/kg crystalloid for hypotension or lactate  $\geq 4$  mmol/L

#### **TO BE COMPLETED WITHIN 6 HOURS:**

- 5) Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to maintain a mean arterial pressure (MAP)  $\geq 65$  mm Hg
- 6) In the event of persistent arterial hypotension despite volume resuscitation (septic shock) or initial lactate  $\geq 4$  mmol/L (36 mg/dL):
  - Measure central venous pressure (CVP)\*
  - Measure central venous oxygen saturation (Scvo<sub>2</sub>)\*
- 7) Remeasure lactate if initial lactate was elevated\*

\*Targets for quantitative resuscitation included in the guidelines are CVP of  $\geq 8$  mm Hg, Scvo<sub>2</sub> of  $\geq 70\%$ , and normalization of lactate.

Surviving Sepsis  
Campaign **2018**

SPECIAL EDITORIAL

The Surviving Sepsis Campaign Bundle:  
2018 update



Mitchell M. Levy<sup>1\*</sup>, Laura E. Evans<sup>2</sup> and Andrew Rhodes<sup>3</sup>

Bundle element

Measure lactate level. Re-measure if initial lactate is  $> 2$  mmol/L

Obtain blood cultures prior to administration of antibiotics

Administer broad-spectrum antibiotics

Rapidly administer 30 ml/kg crystalloid for hypotension or lactate  $\geq 4$  mmol/L

Apply vasopressors if patient is hypotensive during or after fluid resuscitation to maintain  
MAP  $\geq 65$  mm Hg





# Score systems




**Review**

The beginning of personalized medicine  
in sepsis: small steps to a bright future



# Genetic background


single nucleotide polymorphisms (SNPs)



**MIF, TLR,**  
**TNF** →

Better bacterial kill, but higher mortality of septic shock especially when induced by DAMP

Alleles	Mortality
AA	48,7 %
AG	30,5 %
GG	29,5 %



AA genotype ADRB2 rs1042717 G/A polymorphism and beta-blocker treatment:

- increased heart rate
- more organ failure
- higher mortality

**But can be reversed by low dose steroids!**

## Gene Expression Profiles Differentiate Between Sterile SIRS and Early Sepsis

*Steven B. Johnson, MD,\* Matthew Lissauer, MD,\* Grant V. Bochicchio, MD, MPH,\*  
Richard Moore, MD, PhD,† Alan S. Cross, MD,‡ and Thomas M. Scalea, MD\**

*Annals of Surgery • Volume 245, Number 4, April 2007*

**12,782 genes (23.4%) with different expression within 0-48 hrs in sepsis compared to SIRS**

**Innate immunity:** via TLR és MAPK

**Citokine receptors:** IL22 soluble receptor, citokine-citokine receptor interaction, IL-1R signal transduction

**T-cell differentiation:** Interferon Signaling Pathway, TH1/TH2 Differentiation Pathway, IL-12 and STAT4 Dependent Signaling Pathway

**Protein synthesis regulation:** apoptosis, eIF-4E and p70 S6 Kinase Pathway

RESEARCH

Open Access

# Genome-wide transcription profiling of human sepsis: a systematic review

Benjamin M Tang<sup>1,2\*</sup>, Stephen J Huang<sup>1</sup>, Anthony S McLean<sup>1</sup>




Figure 1 Study selection

**Results:** We identified 12 cohorts consisting of 784 individuals providing genome-wide expression data in early and late sepsis. Sepsis elicited an immediate activation of pathogen recognition receptors, accompanied by an increase in the activities of signal transduction cascades. These changes were consistent across most cohorts. However, changes in inflammation related genes were highly variable. Established inflammatory markers, such as tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-1 or interleukin-10, did not show any consistent pattern in their gene-expression across cohorts. The finding remains the same even after the cohorts were stratified by timing (early vs. late sepsis), patient groups (paediatric vs. adult patients) or settings (clinical sepsis vs. endotoxemia model). Neither a distinctive pro/anti-inflammatory phase nor a clear transition from a pro-inflammatory to anti-inflammatory phase could be observed during sepsis.

**Conclusions:** Sepsis related inflammatory changes are highly variable on a transcriptional level. We did not find strong genomic evidence that supports the classic two phase model of sepsis.

PRR, signal trasduction: similar  
Inflammatory citokines (TNF, IL-1, IL-10): totally inhomogenous activation

RESEARCH

Open Access

## Host genetic variants in sepsis risk: a field synopsis and meta-analysis



Hongxiang Lu<sup>1</sup>, Dalin Wen<sup>1</sup>, Xu Wang<sup>1,2</sup>, Lebin Gan<sup>1,3</sup>, Juan Du<sup>1</sup>, Jianhui Sun<sup>1</sup>, Ling Zeng<sup>1</sup>, Jianxin Jiang<sup>1\*</sup> and Anqiang Zhang<sup>1\*</sup>

- 349 eligible articles focusing on 405 variants of 172 distinct genes.
- 29 variants of 23 genes significantly associated with the **risk of sepsis** (8 for PRRs, 14 for cytokines, 1 immune-related gene and 6 variants of other genes)
- Several genetic variants that could influence the **susceptibility to sepsis**

Research Article



**Prospective Testing and Redesign of a Temporal Biomarker Based Risk Model for Patients With Septic Shock: Implications for Septic Shock Biology**



Hector R. Wong <sup>AB,\*,</sup> Natalie Z. Cvijanovich <sup>c,</sup> Nick Anas <sup>d,</sup> Geoffrey L. Allen <sup>e,</sup> Neal J. Thomas <sup>f,</sup> Michael T. Bigham <sup>g,</sup> Scott L. Weiss <sup>h,</sup> Julie Fitzgerald <sup>h,</sup> Paul A. Checchia <sup>i,</sup> Keith Meyer <sup>i,</sup> Michael Quasney <sup>k,</sup> Mark Hall <sup>l,</sup> Rainer Gedeit <sup>m,</sup> Robert J. Freishtat <sup>n,</sup> Jeffrey Nowak <sup>o,</sup> Shekhar S. Raj <sup>p,</sup> Shira Gertz <sup>q,</sup> Kelli Howard <sup>r,</sup> Kelli Harmon <sup>s,</sup> Patrick Lahni <sup>s,</sup> Erin Frank <sup>s,</sup> Kimberly W. Hart <sup>t,</sup> Christopher J. Lindell <sup>t</sup>

Based on measurements on day 1. and 3.

- Interleukin- 8 (IL8)
- C chemokine ligand 3 (CCL3)
- Matrix metalloproteinase 9 (MMP8)




excessive inflammation




strong immunosuppression

**High mortality in each case but with different causes!**





# Biomarkers




Persistent **changes** in immunity




Individual differences

Interindividual differences



# Evaluation of Procalcitonin for Predicting Septic Multiorgan Failure and Overall Prognosis in Secondary Peritonitis

Arch Surg. 2007;142:134-142



**Absolute value < 0.5 ng/ml OR a decrease > 80 % of the peak value**

- Procalcitonin concentrations were most closely correlated with the development of septic multiorgan dysfunction syndrome.
- **Persisting procalcitonin levels** greater than 1.0 ng/mL beyond the first week after disease onset **strongly indicated nonsurvival** and were significantly better than CRP in assessing overall prognosis (P<.001).

# Clec'h et al.: Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock Crit Care Med. 2006, 34:102-107

## Medical patients:

SIRS PCT: 0,3 ng/ml (0,1-1)

Septic shock PCT: 8,4 ng/ml (3,6-76)



## Surgical patients:

SIRS PCT: 5,7 ng/ml (2,6-8.35)

Septic shock PCT: 34 ng/ml (7-76)



**Medical patients = PAMP and maybe DAMP**  
**Surgical patients = clearly DAMP and maybe PAMP**






<https://myheart.net/heart-disease/heart-failure/>



Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. *Am J Cardiol* 1997; 79: 1426-1430.

# Antibiotics for what?




## The role of procalcitonin in acute heart failure patients

Martin Möckel<sup>1,2\*</sup>, Julia Searle<sup>2</sup> and Alan Maisel<sup>3</sup>

Figure 1 Proposed future use of procalcitonin in acute heart failure (AHF) using the cut-offs currently investigated in the IMPACT study. Established cut-offs are listed in Table 1. BNP, brain natriuretic peptide; ED, emergency department; MR-proANP, midregional pro-atrial natriuretic peptide; NT-proBNP, N terminal pro brain natriuretic peptide.


### Potential PCT-guided algorithm for the use of antibiotics in AHF-patients




Review Article

**Advanced Hemodynamic Management in Patients with Septic Shock**

Bernd Saugel,<sup>1</sup> Wolfgang Huber,<sup>2</sup> Axel Niehaus,<sup>3</sup> Stefan Kluge,<sup>3</sup> Daniel A. Reuter,<sup>1</sup> and Julia Y. Wagner<sup>1</sup>



**Initial values?  
Individual figures?  
Are you OK with 140/85?**



[Sex-Specific Analysis of Cardiovascular Function](#) pp 307-328 | [Cite as](#)

## Sex-Specific Characteristics of the Microcirculation

Authors

[Authors and affiliations](#)

Virginia H. Huxley , Scott S. Kemp

Chapter



First Online: 27 July 2018

1

318

„...focusing on the constituents of the microcirculation identifies what is known presently about the role sex plays in matching metabolic demand with microvascular function and areas requiring additional study. Many of the identified sex differences are subtle and easily ignored. In the aggregate, though, they can profoundly alter phenotype, especially under stressful conditions including pregnancy, exercise, and disease states ranging from diabetes to heart failure.”





*Review Article*  
**Sepsis: From Pathophysiology to Individualized Patient Care**

Hilla Ezerkani<sup>1</sup>, Thomas von Thiel<sup>2</sup>, Zoltán Molnár<sup>3</sup> and Hans Förstner<sup>2</sup>



J Immun Res, 2015, AID:510436



<https://www.sott.net/article/318261-Dr-Justin-Sonnenburg-Is-a-disrupted-gut-microbiome-at-the-root-of-modern-disease>

# The role of the microbiome in human health and disease: an introduction for clinicians

Vincent B Young



# *Functions – superficial overlook*

Own microbial needs

Needs of host organism

„Messed up” processes of host  
organism



Local and systemic events

# Possible sites of intervention

Approach	Rational	Example
<b>Antibiotics</b>	Target specific members or groups of the microbiota and suppress them, allowing expansion of desirable species	Small intestinal bacterial overgrowth Hepatic encephalopathy
<b>Bacteriophages</b>	Use naturally occurring bacterial viruses to target specific members of a community that are disruptive or are carrying out pathogenic processes	Pathogen targeted therapy to spare the microbiota from collateral damage
<b>Probiotics (single species)</b>	Replace a presumably missing organism and thus a missing function in the form of an organism	<i>Saccharomyces boulardii</i> for prevention of antibiotic associated diarrhea
<b>Multispecies/designer communities</b>	As with single species probiotics, use a collection of organisms to replace a missing function in the microbiome	Feces derived communities, multispecies
<b>Prebiotics</b>	Supply a complex food product (often carbohydrates) that is not digestible by the host to stimulate specific members of the microbiota. The prebiotic is meant to be metabolized by the microbiota to compounds beneficial to the host	Inulin, resistant starch
<b>Synbiotics</b>	Supply a complex of a microbe or microbes along with a prebiotic that is meant to be used by these organisms replace a missing function in a microbiome	
<b>Nutritional therapy</b>	Complete redesign of a diet to promote beneficial microbial communities and function	Low FODMAP diet for IBS. Exclusive enteral nutritional therapy for IBD
<b>Community replacement, "microbiota restoration"</b>	To restore a "deficient" microbiota, harvest a presumably normal microbiota from a healthy person and administer it to a patient	Fecal transplantation

FODMAP=fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IBS=irritable bowel syndrome; IBD=inflammatory bowel disease.

Surviving Sepsis Campaign **2018**

**SPECIAL EDITORIAL**

The Surviving Sepsis Campaign Bundle:  
2018 update



Mitchell M. Levy<sup>1</sup>, Laura E. Evans<sup>2</sup> and Andrew Rhodes<sup>3</sup>

Bundle element	Grade of recommendation and level of evidence
Measure lactate level. Re-measure if initial lactate is > 2 mmol/L	Weak recommendation, low quality of evidence
Obtain blood cultures prior to administration of antibiotics	Best practice statement
Administer broad-spectrum antibiotics	Strong recommendation, moderate quality of evidence
Rapidly administer 30 ml/kg crystalloid for hypotension or lactate $\geq$ 4 mmol/L	Strong recommendation, low quality of evidence
Apply vasopressors if patient is hypotensive during or after fluid resuscitation to maintain MAP $\geq$ 65 mm Hg	Strong recommendation, moderate quality of evidence

# Antibiotics vs microbiome



[ Original Research Critical Care ]

CHEST



## Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States

Robert A. Balk, MD; Sameer S. Kadri, MD; Zhun Cao, PhD; Scott B. Robinson, MA, MPH; Craig Lipkin, MS; and Samuel A. Bozzette, MD, PhD

CHEST 2017; 151(1):23-33








TABLE 2 | Matched Outcomes Without Regression Adjustment



Variable	1 to 2 PCT Assessments Within 1 Day of ICU Admission (n = 33,560 discharges)		No PCT (n = 98,543 discharges)		Difference		PCT vs No PCT, P Value
	Mean	95% CI	Mean	95% CI	Mean	95% CI	
LOS, d	10.5	10.4 to 10.6	12.8	12.7 to 12.9	-2.3	-2.4 to -2.2	< .001
ICU LOS, d	4.8	4.8 to 4.9	5.6	5.5 to 5.6	-0.7	-0.8 to -0.7	< .001
Total cost, \$	25,513	25,163 to 25,864	33,164	32,898 to 33,429	-7,650	-8,090 to -7,211	< .001
ICU cost, \$	16,814	16,560 to 17,069	21,630	21,429 to 21,832	-4,816	-5,140 to -4,492	< .001
Pharmacy cost, \$	3,866	3,694 to 4,038	4,589	4,494 to 4,684	-723	-920 to -527	< .001
Antibiotic cost, \$	832	768 to 897	936	911 to 961	-103	-173 to -34	< .001
Laboratory cost, \$	1,457	1,442 to 1,472	1,710	1,697 to 1,724	-253	-274 to -233	< .001
Room and board cost, \$	12,212	12,053 to 12,370	15,379	15,254 to 15,503	-3,167	-3,369 to -2,965	< .001
Total antibiotic exposure <sup>a</sup>	14.9	14.7 to 15.0	17.3	17.2 to 17.4	-2.4	-2.6 to -2.3	< .001
Inpatient mortality	19.3%	18.8 to 19.7	18.2%	18.0 to 18.5	1.1%	0.6 to 1.5	< .001
Home	43.8%	43.3 to 44.4	41.4%	41.1 to 41.7	2.4%	1.8 to 3.1	< .001
Hospice	6.3%	6.1 to 6.6	6.4%	6.2 to 6.6	-0.1%	-0.4 to 0.2	.617
Other	1.7%	1.6 to 1.9	1.6%	1.5 to 1.7	0.1%	0 to 0.3	.122
Transfer to SNF/ICF/LTC	22.7%	22.2 to 23.1	25.2%	24.9 to 25.4	-2.5%	-3.0 to -2.0	< .001
Transfer to acute care	6.2%	5.9 to 6.4	7.2%	7.0 to 7.4	-1.0%	-1.3 to -0.7	< .001

- Decreased LoS and ICU LoS
- Lower hospital costs
- Less total antibiotic exposure
- **More patients to be discharged to home**


# OMICS...



# Precision medicine



<https://healthmatters.nyp.org/precision-medicine/>



## Street lamp effect vs panorama picture



